Back to search

Article

Optimal Treatment Strategies for EGFR Mutant Advanced Lung Adenocarcinoma Patients with Targeted Therapy Resistance and Correlation Analysis of PD-L1 Expression with ICI Efficacy

2025-11-17

Abstract excerpt

<title>Abstract</title> <p>Background Third-generation tyrosine kinase inhibitors (TKIs) have become the standard treatment for advanced epidermal growth factor receptor (EGFR)-mutated lung adenocarcinoma. Currently, after developing resistance to third-generation EGFR-TKIs, treatment regimens based on platinum-based dual-agent chemotherapy yield limited clinical benefit. Method This retrospective study analyzed...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
030c957e-3d68-5516-91ce-6c58d7863749
DOI
10.21203/rs.3.rs-7774591/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Optimal Treatment Strategies for EGFR Mutant Advanced Lung Adenocarcinoma Patients with Targeted Therapy Resistance and Correlation Analysis of PD-L1 Expression with ICI EfficacyDOI 10.21203/rs.3.rs-7774591/v1
Optimal treatment strategies for EGFR mutant advanced lung adenocarcinoma patients with targeted therapy resistance and correlation analysis of PD-L1 expression with ICI efficacy.Semantic proximity
Efficacy of ICI-based treatment in advanced NSCLC patients with PD-L1≥50% who developed EGFR-TKI resistance.Semantic proximity
Multimodal profiling for prediction of primary resistance to anti–PD-(L)1 therapy in advanced non-small-cell lung cancer: the prospective PIONeeR biomarkers studySemantic proximity
Enhancing First-Line TKI Efficacy in PD-L1-Positive EGFR-Mutated NSCLC: The Role of Antiangiogenic AgentsSemantic proximity
Comparison of Post-Resistance Treatment Outcomes in EGFR-Mutated NSCLC Patients Following Third-Generation EGFR-TKI Therapy: A Retrospective Cohort Study.Semantic proximity
Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.Semantic proximity
PD-L1 Expression and Histopathological Features in EGFR-Mutated Non-Small Cell Lung Cancer: Implications for Immune Checkpoint Inhibitors After EGFR-Tyrosine Kinase Inhibitors Resistance.Semantic proximity
Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.Semantic proximity
Chemotherapy versus personalized therapy for EGFR mutant lung adenocarcinoma resistance to EGFR-Tyrosine Kinase Inhibitors: A Retrospective Dual-Center StudySemantic proximity
First-line treatment for driver gene–negative metastatic lung adenocarcinoma with malignant pleural effusion: Should chemotherapy be combined with an immune checkpoint inhibitor or bevacizumab？Semantic proximity
Outcome of non-small-cell lung cancer with driven mutations treated with anti-PD-(L)1 agents: A systematic review.Semantic proximity
Comparison of efficacy and safety between PD-1 inhibitors and PD- L1 inhibitors plus platinum-etoposide as first-line treatment for extensive-stage small-cell lung cancer: a multicenter, real-world analysisSemantic proximity
Select a neighboring publication to make it the new centre.